Cargando…

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents

BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was...

Descripción completa

Detalles Bibliográficos
Autores principales: He, G, Kuang, J, Koomen, J, Kobayashi, R, Khokhar, A R, Siddik, Z H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817341/
https://www.ncbi.nlm.nih.gov/pubmed/24104967
http://dx.doi.org/10.1038/bjc.2013.613
_version_ 1782478059747672064
author He, G
Kuang, J
Koomen, J
Kobayashi, R
Khokhar, A R
Siddik, Z H
author_facet He, G
Kuang, J
Koomen, J
Kobayashi, R
Khokhar, A R
Siddik, Z H
author_sort He, G
collection PubMed
description BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated. METHODS: Ovarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry. RESULTS: The active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ∼140 kDa, which increased to ∼290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ∼150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21. CONCLUSION: G1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex.
format Online
Article
Text
id pubmed-3817341
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38173412014-10-29 Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents He, G Kuang, J Koomen, J Kobayashi, R Khokhar, A R Siddik, Z H Br J Cancer Translational Therapeutics BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated. METHODS: Ovarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry. RESULTS: The active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ∼140 kDa, which increased to ∼290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ∼150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21. CONCLUSION: G1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex. Nature Publishing Group 2013-10-29 2013-10-08 /pmc/articles/PMC3817341/ /pubmed/24104967 http://dx.doi.org/10.1038/bjc.2013.613 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Translational Therapeutics
He, G
Kuang, J
Koomen, J
Kobayashi, R
Khokhar, A R
Siddik, Z H
Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title_full Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title_fullStr Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title_full_unstemmed Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title_short Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
title_sort recruitment of trimeric proliferating cell nuclear antigen by g1-phase cyclin-dependent kinases following dna damage with platinum-based antitumour agents
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817341/
https://www.ncbi.nlm.nih.gov/pubmed/24104967
http://dx.doi.org/10.1038/bjc.2013.613
work_keys_str_mv AT heg recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents
AT kuangj recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents
AT koomenj recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents
AT kobayashir recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents
AT khokharar recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents
AT siddikzh recruitmentoftrimericproliferatingcellnuclearantigenbyg1phasecyclindependentkinasesfollowingdnadamagewithplatinumbasedantitumouragents